Modeling atrial fibrosis in vitro-Generation and characterization of a novel human atrial fibroblast cell line.
Stephan R KünzelJohanna S E RauschCharlotte SchäfferMaximilian HoffmannKarolina KünzelErik KlapprothTheresa KantNatalie HerzogJan-Heiner KüpperKristina LorenzSvenja DudekRamona EmigUrsula RavensEva A Rog-ZielinskaRémi PeyronnetAli El-ArmouchePublished in: FEBS open bio (2020)
Atrial fibrillation (AF) is regularly accompanied by cardiac fibrosis and concomitant heart failure. Due to the heterogeneous nature and complexity of fibrosis, the knowledge about the underlying mechanisms is limited, which prevents effective pharmacotherapy. A deeper understanding of cardiac fibroblasts is essential to meet this need. We previously described phenotypic and functional differences between atrial fibroblasts from patients in sinus rhythm and with AF. Herein, we established and characterized a novel human atrial fibroblast line, which displays typical fibroblast morphology and function comparable to primary cells but with improved proliferation capacity and low spontaneous myofibroblast differentiation. These traits make our model suitable for the study of fibrosis mechanisms and for drug screening aimed at developing effective antifibrotic pharmacotherapy.
Keyphrases
- atrial fibrillation
- catheter ablation
- heart failure
- left atrial
- oral anticoagulants
- endothelial cells
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- left ventricular
- percutaneous coronary intervention
- induced pluripotent stem cells
- healthcare
- ejection fraction
- chronic kidney disease
- induced apoptosis
- pluripotent stem cells
- smoking cessation
- oxidative stress
- gene expression
- cell proliferation
- blood pressure
- dna methylation
- cell cycle arrest
- patient reported outcomes
- genome wide
- wound healing
- coronary artery disease
- transforming growth factor
- mouse model
- cardiac resynchronization therapy